Altimmune, Inc. (ALT) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ALT Revenue Growth
Revenue Breakdown (FY 2021)
ALT's revenue distribution by segment and geography for fiscal year 2021
By Product/Segment
ALT Revenue Analysis (2014–2025)
As of May 8, 2026, Altimmune, Inc. (ALT) generated trailing twelve-month (TTM) revenue of $41,000, reflecting explosive growth of +420.0% year-over-year. The most recent quarter (Q4 2025) recorded $26,000 in revenue, up 420.0% sequentially.
Looking at the longer-term picture, ALT's 5-year compound annual growth rate (CAGR) stands at -65.3%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $10.6 million in 2015.
Revenue diversification analysis shows ALT's business is primarily driven by Grant (100%). With over half of revenue concentrated in Grant, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including NRXP. Compare ALT vs NRXP →
ALT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ALTCurrent | $41,000 | +420.0% | -65.3% | -230461.0% | |
 NRXP | $1M | - | - | -1324.4% |
ALT Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $41K | +105.0% | $0 | - | $-94,489,000 | -230461.0% |
| 2024 | $20K | -95.3% | $20K | 100.0% | $-103,172,000 | -515860.0% |
| 2023 | $426K | +726.5% | $426K | 100.0% | $-95,929,000 | -22518.5% |
| 2022 | $-68,000 | -101.5% | $-68,000 | 100.0% | $-87,740,000 | 129029.4% |
| 2021 | $4.4M | -46.1% | $4.4M | 100.0% | $-96,914,000 | -2197.6% |
| 2020 | $8.2M | +41.1% | $-25,324,291 | -309.4% | $-54,798,741 | -669.5% |
| 2019 | $5.8M | -43.8% | $5.8M | 100.0% | $-21,464,935 | -370.0% |
| 2018 | $10.3M | +24792.6% | $-8,128,142 | -78.7% | $-42,834,410 | -414.6% |
| 2017 | $42K | -99.2% | $-18,364,826 | -44249.4% | $-52,045,259 | -125401.2% |
| 2016 | $5.2M | -50.8% | $-1,991,264 | -38.1% | $-11,264,347 | -215.4% |
See ALT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ALT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ALT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonALT — Frequently Asked Questions
Quick answers to the most common questions about buying ALT stock.
Is ALT's revenue growth accelerating or slowing?
ALT revenue is accelerating at +420.0% year-over-year, exceeding the 5-year CAGR of -65.3%. TTM revenue reached $41000.00. Growth momentum has increased versus prior periods.
What is ALT's long-term revenue growth rate?
Altimmune, Inc.'s 5-year revenue CAGR of -65.3% reflects the sustained expansion pattern. Current YoY growth of +420.0% is above this long-term average.
How is ALT's revenue distributed by segment?
ALT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.